Digestive fistulas after cytoreductive surgery & HIPEC in peritoneal carcinomatosis

• Published in: Journal of B.U. ON. Vol. 20 Suppl 1; p. S60
• Main Authors: Halkia, Evgenia, Efstathiou, Elias, Rogdakis, Athanassios, Christakis, Christos, Spiliotis, John
• Format: Journal Article
• Language: English
• Published: Greece 01.05.2015
• Subjects: Adult; Aged; Antineoplastic Agents - administration & dosage; Combined Modality Therapy; Cytoreduction Surgical Procedures - adverse effects; Digestive System Fistula - etiology; Female; Humans; Hyperthermia, Induced - adverse effects; Injections, Intraperitoneal; Male; Middle Aged; Peritoneal Neoplasms - therapy
• ISSN: 1107-0625

The development of digestice fistulas is a complication of gastrointestinal operations during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). In this article we present the incidence, management and outcome of enterocutaneous digestive fistulas after CRS and HIPEC. Over the past 10 years (2005-2014), 184 patients with peritoneal carcinomatosis underwent CRS and HIPEC. HIPEC was administered in the operating room immediately after CRS, but in 48 (26%) patients this happened before the formation of intestinal anastomosis or repair of seromuscular tears, using the open (coliseum) technique; in the remaining 137 (74%) patients the anastomoses were performed before HIPEC. All patients were operated on by the same surgical team. Of the 185 patients 16 (8.6%) developed an enterocutaneous digestive fistula. Spontaneous fistula closure was observed in 14 (87.5%) patients. The median duration of spontaneous closure was 18 days (range 9-56). Reoperation was needed in 2 (12.5%) patients. There were 2 (12.5%) deaths. CRS and HIPEC is a well-known treatment modality for peritoneal carcinomatosis. The incidence of digestive fistulas is increased a little compared to that of conventional digestive surgery.